Inflammation-targeted therapies and cancer

Kedra, Joanna; Nocturne, Gaëtane; Mariette, Xavier; Séror, Raphaèle

doi:10.1016/j.jbspin.2021.105176

Cited by 3 publications

(2 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is an increased risk of lymphoma in patients with auto-immune diseases (AID) especially rheumatoid arthritis (RA) and primary Sjögren Syndrome (pSS) with a respective relative risk of 2 and 15 [1]. The mechanisms promoting lymphomagenesis in AID might be diverse [2]. Disease activity and chronic antigenic stimulation of autoimmune B cells play a key role in lymphomagenesis associated with pSS [3].…”

Section: Abstract: Rheumatoid Arthritis Lymphoma Tnfaip3 A20 Single N...mentioning

confidence: 99%

Lack of association between the TNFAIP3 rs2230926 variant and rheumatoid arthritis-associated lymphoma

et al. 2022

Self Cite

View full text Add to dashboard Cite

Section: Abstract: Rheumatoid Arthritis Lymphoma Tnfaip3 A20 Single N...mentioning

confidence: 99%

Lack of association between the TNFAIP3 rs2230926 variant and rheumatoid arthritis-associated lymphoma

et al. 2022

Self Cite

View full text Add to dashboard Cite

“…The risk of malignancy in patients with rheumatoid arthritis (RA) is globally similar to that of the general population except for increased risk of lung cancer and lymphoma,1–3 the former likely linked to smoking, and the latter to long-term activity of the disease 4 5. Thus, acting by controlling disease activity, disease-modifying antirheumatic agents (DMARDs) might decrease the overall risk of lymphoma 6.…”

Section: Introductionmentioning

confidence: 99%

Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare database

et al. 2022

Self Cite

View full text Add to dashboard Cite

ObjectiveTo compare the risk of malignancy between patients with rheumatoid arthritis (RA) initiating their first biological disease-modifying antirheumatic drug (bDMARD) and those continuing conventional synthetic DMARDs (csDMARDs).MethodsNine-year historical Propensity Score (PS) matched cohort study within the French national healthcare database (87% of the French population; ~57 million people), including adults RA without malignancy. Exposures started with the first use of any systemic treatment (csDMARDs and/or bDMARDs). Incident users of bDMARDs were matched on a dynamic PS to patients continuing csDMARDs. Their risk of malignancy was compared by Cox model.ResultsFrom 1 January 2007 to 31 December 2014, 83 706 patients with RA started their first systemic treatment (63 837 remained on csDMARDs and 19 869 initiated a bDMARD during follow-up). After dynamic PS matching, 19 727 bDMARD initiators were compared with 19 727 RA remaining on csDMARDs. They did not statistically differ in risk of overall malignancies (HR 0.99 (95% CI 0.86 to 1.14)), solid cancer (HR 0.95 (95% CI 0.82 to 1.11)), nor lymphoma (HR 1.35 (95% CI 0.72 to 2.53)). Results were similar when bDMARDs were given as monotherapy or in association with csDMARDs. Analyses restricted to patients starting TNF inhibitor as first bDMARD compared with matched RA remaining on csDMARDs, provided similar results (HR for overall malignancy 1.03 (95% CI 0.88 to 1.21)). Sensitivity analyses, varying carry-over periods (up to 5 years) to define risk periods, provided similar results.ConclusionsIn this historical cohort study within the French nationwide healthcare database, the risk of overall, solid or haematological malignancies did not significantly differ between patients with RA initiating bDMARD and those continuing csDMARDs.

show abstract

Evaluation of the incidence of melanoma and non-melanoma skin cancer in patients with systemic lupus erythematosus and systemic sclerosis

FUSANO,

SOGLIA,

FRANCESCHINI

et al. 2024

Ital J Dermatol Venereol

View full text Add to dashboard Cite

Inflammation-targeted therapies and cancer

Cited by 3 publications

References 73 publications

Lack of association between the TNFAIP3 rs2230926 variant and rheumatoid arthritis-associated lymphoma

Lack of association between the TNFAIP3 rs2230926 variant and rheumatoid arthritis-associated lymphoma

Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare database

Evaluation of the incidence of melanoma and non-melanoma skin cancer in patients with systemic lupus erythematosus and systemic sclerosis

Contact Info

Product

Resources

About